Embolotherapy Market Share, Size and Growth Analysis By 2029

The embolotherapy sector is projected to expand from US$ 3,341.49 million in 2021 to US$ 5,758.28 million by 2028, reflecting a compound annual growth rate (CAGR) of 8.1% from 2022 to 2028.

This report outlines the prevailing trends and key factors propelling the growth of the embolotherapy market. The increase in market size is primarily driven by a surge in cancer diagnoses, a growing preference among patients for minimally invasive treatment options, and a rise in conditions such as hypertension, obesity, smoking, and alcohol dependency. Conversely, the presence of alternative treatment options and the high costs associated with embolization agents pose challenges to market expansion.

Embolotherapy involves the occlusion of blood vessels through the introduction of materials such as balloons, blood clots, coils, or gel foam via an angiographic catheter. This catheter facilitates the blockage of blood vessels to manage bleeding ulcers, close fistulas or arteriovenous malformations, devascularize organs, rectify blood vessel defects, or control inoperable hemorrhages. Additionally, embolotherapy is employed to restrict blood flow to tumors during surgical procedures.

The five most prevalent cancer types include breast, prostate, cervical, lung, and colorectal cancers. Among these, lung cancer remains the leading cause of cancer-related mortality. Despite breast cancer having a higher incidence rate among women, cervical cancer was the primary cause of cancer deaths in 2020. According to the National Cancer Registry (NCR), approximately 110,000 new cancer cases were reported in South Africa in 2020, resulting in over 56,000 cancer-related fatalities, which accounted for a quarter of premature deaths linked to noncommunicable diseases. This significant cancer burden is expected to escalate in the coming decades, with projections indicating that new cancer cases could rise to 138,000 and 175,000 by 2030 and 2040, respectively. Cancer-related deaths are anticipated to increase to 73,000 and 94,000 during the same timeframe. Furthermore, the American Cancer Society estimates that in 2021, around 1.9 million new cancer cases and 608,570 cancer deaths occurred in the United States. In Denmark, the cancer incidence rate was reported at 334.9 per 100,000 individuals, with ten countries, including Denmark, Hungary, and Ireland, showing age-standardized rates exceeding 300 per 100,000. In Germany, approximately 233,000 women and 265,000 men were newly diagnosed with cancer in 2018, with the annual new case count stabilizing around 500,000 for the past decade. Thus, the increasing prevalence of cancer is driving demand for embolotherapy solutions.

The embolotherapy market is categorized by product type into embolic agents and support devices. The embolic agents segment is further divided into microspheres, liquid embolic agents, embolic coils, embolic plug systems, detachable balloons, and others. Support devices include microcatheters and guidewires. The embolic agents segment is expected to dominate the market share in 2021 and is projected to exhibit the highest CAGR during the forecast period, driven by the growing utilization of embolic agents in interventional radiology and advancements in these agents.

In terms of disease indication, the embolotherapy market is segmented into cancer, peripheral vascular disease, neurological disorders, urological and nephrological disorders, gastrointestinal disorders, and others. The cancer segment, which includes liver and kidney cancers, is anticipated to hold the largest market share in 2021 and is expected to grow at the fastest rate from 2022 to 2028, fueled by the rising global incidence of cancer.

Additionally, the market is segmented by treatment type into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). The TAE segment is projected to capture the largest market share in 2021 and is expected to experience the highest CAGR from 2022 to 2028, driven by the increasing preference for minimally invasive procedures among older patients, the rising prevalence of chronic diseases, and the rapid growth of the aging population.

From an end-user perspective, the embolotherapy market is divided into hospitals and clinics, ambulatory surgical centers, and other facilities. The hospitals and clinics segment is expected to hold the largest market share in 2021 and is projected to register the highest CAGR from 2022 to 2028. This growth is attributed to the increasing adoption of minimally invasive surgical techniques, a higher patient influx in hospitals for various treatments, and the growing number of embolization procedures performed in these settings.

Impact of COVID-19 on the Embolotherapy Market

The COVID-19 pandemic has posed significant challenges in managing cancers, particularly in head and neck surgeries, and chronic neurological disorders. Many patients have faced delays in treatment, leading to complications and late presentations in emergency departments. The pandemic resulted in the cancellation of elective surgeries, affecting patients' quality of life, particularly those with conditions like uterine fibroids. Despite these challenges, hospitals have continued to provide Uterine Fibroid Embolization (UFE) services during the pandemic, although the initial impact on market growth was negative.

Companies in the embolotherapy market are employing various organic and inorganic strategies to enhance their market presence. Organic strategies include product launches and approvals, while inorganic strategies involve acquisitions, collaborations, and partnerships. These strategies enable market players to expand their operations and improve their geographic reach. Notable developments in the embolotherapy market include:

• In April 2022, Boston Scientific Corporation received 510(k) clearance from the US FDA for the EMBOLD Fibered Detachable Coil, designed to impede blood flow in peripheral vasculature.


• In September 2021, Abbott announced its acquisition of Walk Vascular, LLC, which specializes in a minimally invasive mechanical aspiration thrombectomy system for removing peripheral blood clots.

Key sources referenced in the preparation of this report include the World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI).